US › Healthcare

Altimmune Inc (ALT)

US · Healthcare · Biotechnology

$3.07+2.33%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-22.6M
Profit YoY
-15.3%
EPS
$-0.18
EPS estimate
$-0.25

EPS came in at -0.18 against a street estimate of -0.25 — a beat of 28.0%.

Key statistics

Market cap
$583.4M
Forward P/E
8.2
P/B
1.95
Book value
$2.18
EPS (TTM)
$-0.97
52-week high
$6.44
52-week low
$2.56
50-day MA
$2.89
200-day MA
$3.76
Beta
0.17

Analyst view

Analysts rate Altimmune Inc a buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $17.22.

Shareholding

Insiders
0.41%
Institutions
58.25%

Largest institutional holders

FundStake
BlackRock Inc6.58%
Vanguard Group Inc4.88%
State Street Corp3.67%
Vanguard Capital Management, LLC2.91%
Vanguard Portfolio Management, LLC2.77%
Marshall Wace Asset Management Ltd2.07%
Millennium Management LLC1.68%
Geode Capital Management, LLC1.60%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Altimmune Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.